Impact of culture medium on the expansion of T cells for immunotherapy

Cytotherapy

Volumn 11, Issue 7, 2009, Pages 936-946

  Sato, Keisuke ^a   Kondo, Makoto ^a   Sakuta, Kazuko ^a   Hosoi, Akihiro ^a   Noji, Shuichi ^a   Sugiura, Miki ^a   Yoshida, Yukihiro ^a   Kakimi, Kazuhiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

AIM V; Anti CD3; Culture media; Immunotherapy; OpTmizer; RPMI; T cell expansion; Zoledronate; T cell

Indexed keywords

IMMOBILIZED ANTIBODY; MONOCLONAL ANTIBODY CD3; ZOLEDRONIC ACID;

ARTICLE; CANCER IMMUNOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SERUM; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

EID: 70450161700     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653240903219114     Document Type: Article

References (15)

1. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin. Invest 2008;118:1991-2001.
2. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet 2009;373: 673-683
3. Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006;12:2342-2345
4. Keilholz U, Martus P, Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 2006;12:2346-2352
5. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-2357
6. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-342
7. Kondo M, Sakuta K,Noguchi A,Ariyoshi N, Sato K, Sato S, et al, Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy, Cytothempy 2008;10:842-856
8. Fischer K, Andreesen R, Mackensen A An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods 2002;259:159-169
9. Mesler Muul L, Nason-Burchenal K, Hyatt C, Schwarz S, Slavin D, Director EP, et al. Studies of serum-free culture medium in the generation of lymphokine activated killer cells. J Immunol Methods 1987;105:183-192
10. Jadus MR, Thurman GB, Mrowca-Bastin A, Yannelli JR. The generation of human lymphokine-activated killer cells in various serum-free media. J Immunol Methods 1988; 109:169-174
11. Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, et al, T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun 2007;7:9.
12. Flescher E, Fingrut O. Suppression of interleuldn 2 biosynthesis by three modes of oxidative cellular stress: selective prevention by N-acetyl cysteine. Cytokine 2000;12:495-498
13. Yim CY, Hibbs JB Jr, McGregor JR, Galinsky RE, Samlowski WE. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2. J Immunol 1994; 152:5796-5805
14. Park CS, Park WR, Sugimoto N, Nakahira M, Arm HJ, Hamaoka T, et al. Differential effects of N-acetyl-1-cysteine on IL-2- vs IL-12-driven proliferation of a T cell clone: implications for distinct signalling pathways. Cytokine 2000;12:1419-1422
15. Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies. JImmunother 2004;27:405-418